PHARMA INTEGRATES
2103
London

November 26th-27th

Prof Trevor M Jones CBE.
PhD DSc. FRSC. FRSM. Hon FRCP. FBPharmacolS. F...
…we simply have to do better !!
The Imperatives for Success
• 
• 
• 
• 

Connectivity
Partnerships
Strategic Alliances
Con...
Convergence	
  
	
  
	
  Technologies:
•  biomedicine, engineering, materials science,
computing, robotics, telecommunicat...
Integration/Partnerships
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 

Out sourcing / “Off-shoring”

Discovery support
Clinical Developme...
 

	
  	
  	
  Change is not a choice !!
Partnerships
“If you want to travel fast… go alone
If you want to travel far … go together”
Anon:African proverb
•  Pfizer Splits Up Operations Ahead of Possible
Breakup

•  More than splitting pills: Health care giant Abbott
Laborator...
 

•  AstraZeneca to axe 1,600 jobs in overhaul of drug R&D
•  Teva to reduce workforce by 5000
•  Merck to cut 8500 MORE ...
October 2013

Novartis to cut more than 440 jobs
in Britain
Shire restructuring will lead to loss
of 180 jobs in UK
 
Eighteen GSK China staff held as
whistleblower allegations emerge
China Investigates Sanofi on Bribery
Accusations
Novar...
Main Challenges for the industry ?
Scientific
• MANY new (unvalidated) targets .Increasingly different
(and difficult) pro...
New “Biologicals”
New “Biologicals”

Cell Therapy
Permanent Replacement
Cell Therapy
Tissue Engineering
Permanent Replacem...
 	
  

…so much more to come !!!
Many “new” approaches to therapy
…are you prepared???
The imperative to change the Strategic Agenda
•  Change Focus

•  Growth areas ..speciality, emerging
markets, generics
• ...
Upcoming SlideShare
Loading in …5
×

Pharma Integrates 2013 Keynote Speaker Trevor M Jones CBE

481 views

Published on

Keynote Speaker Trevor M Jones CBE and his keynote address to Pharma Integrates 2013.
Pharma Integrates is an event for senior management in the pharmaceutical industry created and run by Life Sciences Index.

Published in: Business, Technology
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
481
On SlideShare
0
From Embeds
0
Number of Embeds
174
Actions
Shares
0
Downloads
3
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Pharma Integrates 2013 Keynote Speaker Trevor M Jones CBE

  1. 1. PHARMA INTEGRATES 2103 London November 26th-27th Prof Trevor M Jones CBE. PhD DSc. FRSC. FRSM. Hon FRCP. FBPharmacolS. FFPM.FKC
  2. 2. …we simply have to do better !! The Imperatives for Success •  •  •  •  Connectivity Partnerships Strategic Alliances Convergence (Technologies)
  3. 3. Convergence      Technologies: •  biomedicine, engineering, materials science, computing, robotics, telecommunications and web services Cross-sector: •  diagnostics, therapeutics, devices, mobile (m)health, social media, new data mining services
  4. 4. Integration/Partnerships •  •  •  •  •  •  •  •  •  •  Out sourcing / “Off-shoring” Discovery support Clinical Development Data Handling Regulatory Pharmacovigilance Manufacture IT Sales Travel/Meetings/Events ………….etc Connectivity Partnership Strategic Alliances
  5. 5.        Change is not a choice !!
  6. 6. Partnerships “If you want to travel fast… go alone If you want to travel far … go together” Anon:African proverb
  7. 7. •  Pfizer Splits Up Operations Ahead of Possible Breakup •  More than splitting pills: Health care giant Abbott Laboratories ready to spin off AbbVie •  New Novartis Chairman Initiates Strategic Review.
  8. 8.   •  AstraZeneca to axe 1,600 jobs in overhaul of drug R&D •  Teva to reduce workforce by 5000 •  Merck to cut 8500 MORE jobs by 2015 (in addition to the 7500 jobs cut from 2011 to 2012 •  Valeant Pharmaceuticals International Inc said it would cut 10 to 15 percent jobs after buying contact lens maker Bausch & Lomb. Bausch and Lomb employs about 11,000 people worldwide
  9. 9. October 2013 Novartis to cut more than 440 jobs in Britain Shire restructuring will lead to loss of 180 jobs in UK
  10. 10.   Eighteen GSK China staff held as whistleblower allegations emerge China Investigates Sanofi on Bribery Accusations Novartis faces Chinese bribery allegations AUGUST 16, 2013
  11. 11. Main Challenges for the industry ? Scientific • MANY new (unvalidated) targets .Increasingly different (and difficult) product types (Bio/nano/stratified RxDx) • New R&D Models… SME/BigPharma alliances … “learn”& “confirm” Regulatory • Continuing regulatory burden and bureaucracy ….. not just “Q.S.E”………… but, importantly, also “HTA” needs Business • New Markets ...particularly BRIC + • Company restructuring ..M&A ………………..and “cuts” Economic • Continuing “gloomy” Economic Climate
  12. 12. New “Biologicals” New “Biologicals” Cell Therapy Permanent Replacement Cell Therapy Tissue Engineering Permanent Replacement Transient Cell Therapy Tissue Engineering Immunomodulation cell therapy Transient Cell Therapy Cosmoses / bioaesthetics Immunomodulation cell therapy Delivery vehicles Cosmoses / bioaesthetics Cell cancer vaccines Delivery vehicles Xenografts Cell cancer vaccines Regenerative Medicine Xenografts Regenerative Compounds. Regenerative Medicine Regenerative Scaffolds Regenerative Compounds. Regenerative Scaffolds ……….and new Drug Delivery Systems ……….and new Drug Delivery Systems
  13. 13.     …so much more to come !!! Many “new” approaches to therapy …are you prepared???
  14. 14. The imperative to change the Strategic Agenda •  Change Focus •  Growth areas ..speciality, emerging markets, generics •  Fewer areas ,more external ,new •  Narrow R&D R&D models •  Reduce sales force, new techniques, •  Rethink “S&M” shift customer focus •  Reduce fixed infrastructure •  Increase Flexibility •  Outsource •  “Smart” Procurement Re-engineering

×